Preface

This CKS covers plasma dilution as pursued for longevity/rejuvenation — the deliberate reduction of putative “pro-ageing” circulating factors, achieved in practice almost exclusively via therapeutic plasma exchange (TPE) with albumin (± saline) replacement, sometimes termed “old plasma dilution” or “neutral blood exchange”. The concept derives from heterochronic parabiosis work showing that dilution of aged plasma, rather than addition of young factors, drives much of the rejuvenation signal.[1][2] The single most important point for point-of-care use: for healthy longevity clients there are currently no data showing that plasma dilution improves any hard clinical outcome (mortality, morbidity, function). All human evidence rests on surrogate biomarkers (epigenetic clocks, proteomic “age”), the results are inconsistent and even conflicting, and one randomised study found accelerated epigenetic ageing with a plasmapheresis protocol.[3][1][4] Plasma dilution for longevity should therefore be regarded as experimental / only-in-research, offered (if at all) only under a trial or registry framework with rigorous informed consent.

1. Scope

– Covered: rationale, evidence, patient selection, work-up, protocols, monitoring, safety and practical scenarios for plasma dilution/TPE used with the intent of slowing or reversing biological ageing in adults.

– Also touched on for contrast: young-donor plasma exchange and young-plasma infusion (distinct interventions with their own — largely null or preliminary — evidence).[5][6]

– Not covered: established, guideline-based (on-label) TPE indications (e.g. TTP, Guillain–Barré, myasthenic crisis, anti-GBM disease), and TPE for Alzheimer’s disease as a therapeutic indication (referenced only where safety data are informative).[7][8]

– Context: adjunctive to — never a replacement for — conventional primary/secondary care and evidence-based risk-factor management.

2. Background and pathophysiology

– Biological rationale: Ageing is associated with accumulation of circulating pro-inflammatory and “pro-geronic” factors (senescence-associated secretory phenotype [SASP] cytokines, TGF-β, damage signals) and a shift toward an inflammaging proteome. Plasma dilution aims to lower the concentration of these factors and allow a compensatory rebound of youthful/regenerative proteins.[9][10]

– Proposed human mechanisms: A single course of TPE has been reported to shift the circulating proteome toward a younger profile, normalise TLR4-linked NF-κB/JAK-STAT/MAPK/TGF-β signalling, and reduce markers of cellular senescence and DNA damage in circulating cells. A randomised, placebo-controlled TPE study reported rejuvenation across multiple epigenetic clocks and modulation of inflammation-linked proteins, with biweekly TPE+IVIG most active.[1][11]

– Robust human mechanistic evidence is limited: findings come from small studies, are largely proteomic/epigenetic, and are not consistent across protocols (see Evidence base).

Preclinical (clearly separated — mechanistic plausibility only, not a basis for clinical benefit): Heterochronic parabiosis, young-plasma transfer and plasma dilution improve neurogenesis, synaptic plasticity, muscle/liver regeneration and cognition in aged rodents; specific fractions (small EVs, plasma proteins/metabolites) restore mitochondrial function and extend lifespan in animal models.[10][2][12][13] These data motivate but do not validate human use.

3. Evidence base and grading

Available human evidence comprises small RCTs and controlled studies, uncontrolled/real-world cohorts, one systematic review of epigenetic-clock interventions, and large safety datasets from disease-indication TPE. No RCT has assessed mortality, morbidity or validated functional endpoints in healthy adults. All longevity claims rest on surrogate biomarkers of unproven ability to predict clinical benefit when pharmacologically/procedurally modified.

Outcome	Evidence statement	GRADE certainty	Strength of recommendation
Biological age (epigenetic clocks / proteomic age)	Conflicting. One small RCT (n=42) reported rejuvenation across 15 clocks with TPE, strongest for biweekly TPE+IVIG [11]; an uncontrolled study reported proteomic/epigenetic “younging” after TPE [1]. Conversely, a randomised cross-over plasmapheresis study (no albumin/young-plasma replacement) found no rejuvenation and signals of accelerated ageing (↑GrimAge, Hannum, DunedinPACE) [3]. A systematic review concluded plasmapheresis accelerated epigenetic ageing while other interventions lowered it [4].	Low to Very low (small samples, imprecision, inconsistency/heterogeneity of protocols, risk of bias, surrogate indirectness)	Only in research
All-cause mortality / age-related morbidity	No human data in any population for longevity intent.	Very low (no data)	Only in research
Physical function / frailty / performance	No adequately powered human data.	Very low (no data)	Only in research
Cognition (ageing without dementia)	No data in healthy older adults. In AD: young-plasma infusion RCT (PLASMA) showed safety but no cognitive benefit [6]; TPE-albumin (AMBAR programme; real-world replication) suggested slowed decline in mild–moderate AD — a disease indication, not longevity [8]. Young-donor plasma exchange in MCI is a pilot safety study only [5].	Very low for longevity (indirect, different population)	Recommend against outside dementia-specific trials
Cardiometabolic surrogates (lipids)	TPE/plasmapheresis acutely lowers total cholesterol, non-HDL, triglycerides, apolipoproteins — but transiently and non-selectively, alongside falls in total protein/albumin [3]. Not a validated ASCVD-reduction strategy.	Low (surrogate, transient)	Recommend against as a lipid strategy (use guideline therapy)
Safety of the procedure	Large disease-indication datasets show TPE is generally well tolerated; serious events uncommon [7], [14], [15], [16].	Moderate	Procedure acceptably safe in appropriate settings; does not establish benefit

Overall: certainty of benefit is Low-to-Very-low; certainty that the procedure can be performed safely is Moderate. Publication bias and commercial/enthusiast bias are material concerns in this field.[12]

4. Patient selection and indications

There is no evidence-based longevity indication. If offered within a research/registry framework:

– Populations in which a mechanistic case is least implausible (expert-consensus/hypothesis-generating only): adults >50 with a high inflammaging phenotype (elevated hs-CRP/IL-6), or with poorer baseline health where the sole RCT suggested larger biomarker responses. This is not validated for selection.[11]

– Athletic/performance seekers and generally healthy midlife adults: avoid outside trials — no benefit signal and non-trivial cost/risk.

Exclusion / high-risk groups (avoid or specialist input only):

– Haemodynamic instability, significant cardiac or cerebrovascular disease, severe anaemia, coagulopathy or thrombocytopenia, active bleeding.

– Hypoalbuminaemia, malnutrition, significant hepatic impairment (albumin/protein depletion risk).

– Poor vascular access, need for central line in a well person (a key source of serious harm).[15]

– Known IgA deficiency, plasma-product/albumin hypersensitivity, prior anaphylactoid reaction.

– Pregnancy/breastfeeding; frailty with limited reserve; active infection or immunosuppression.

– On ACE inhibitors (risk of atypical/bradykinin reactions with certain apheresis systems) — hold per apheresis protocol.

Regulatory and ethical status (UK):

– Off-label / non-indicated. TPE is an established procedure but has no MHRA/NICE-approved anti-ageing indication. Blood components and their use are regulated under the Blood Safety and Quality Regulations; young-donor plasma exchange raises additional donor-sourcing/regulatory issues, and the US FDA has publicly warned against young-plasma infusions for ageing.

– Practice should be only within a clinical trial or prospective registry, with GMC-standard informed consent that explicitly states: unproven benefit, biomarker-only endpoints, conflicting/negative data, procedural risks, and cost. Framing to patients as “reversing your age” is not supportable.

5. Assessment and baseline work-up

Pre-intervention:

– History and examination: cardiovascular, bleeding, thrombosis and infection risk; medication review (ACE inhibitors, anticoagulants/antiplatelets); vascular access assessment; frailty screen (e.g. Clinical Frailty Scale) in older adults.

– Baseline bloods: FBC, coagulation, U&E, LFTs, serum albumin and total protein, calcium/magnesium/phosphate, fibrinogen, immunoglobulins, hs-CRP, lipid profile, glucose/HbA1c, group & save; virology/consent per apheresis service.

– If used within a study: predefined validated ageing biomarker panel (next-generation epigenetic clocks e.g. DunedinPACE/GrimAge, and/or proteomic panels) collected under standardised conditions — with explicit acknowledgement these are investigational surrogates.[4]

Risk stratification:

– Higher harm risk: central-line requirement, cardiac disease, coagulopathy, hypoalbuminaemia, frailty, ACE inhibitor use.

– “Benefit” cannot currently be predicted reliably; baseline poorer health/higher inflammaging is a hypothesis-only signal.[11]

Baseline documentation: replacement fluid type/volume, estimated plasma volume and % exchanged, vascular access route, and all baseline labs/biomarkers to permit longitudinal interpretation.

6. Dosing regimens and practical implementation

There is no validated longevity protocol; the following describe what has been studied, with certainty flags.

– TPE with albumin replacement (the “plasma dilution” approach) — the regimen with the most (still weak) supportive human data:

– The uncontrolled biological-age study used repeated TPE sessions exchanging roughly one plasma volume with albumin replacement.[1]

– The RCT used biweekly or monthly TPE, with the biweekly TPE + IVIG arm most biomarker-active over months. IVIG adds cost, thrombotic/renal/aseptic-meningitis risk and was the source of a discontinuation-requiring adverse event.[11]

– Disease-indication practice (for reference on tolerability) exchanges ~1–1.5 plasma volumes per session with albumin ± saline; calcium supplementation reduces hypocalcaemia.[16][8]

– Regimens supported by robust human data: none. All longevity regimens are extrapolated from small studies and require caution.

– Plasmapheresis without replacement (Haemonetics-type, no albumin/young plasma): studied in a randomised cross-over trial (4 vs 8 sessions over 18 weeks, ≥2-week intervals) and did not rejuvenate — associated with accelerated epigenetic-clock measures. This protocol should not be used for longevity.[3]

– Young-donor plasma exchange / young FFP infusion: distinct interventions; feasibility/safety pilots only (MCI) or null cognitive results (AD); no longevity data. Not recommended outside trials.[5][6]

No reliable dose–response for a clinical (as opposed to biomarker) endpoint has been established.

7. Monitoring, safety and follow-up

Monitoring:

– Per session: BP/HR, symptoms of hypocalcaemia (perioral/peripheral paraesthesia), citrate reactions, allergic/urticarial reactions, access-site check.

– Labs: calcium (and supplement prophylactically), FBC, coagulation/fibrinogen, albumin/total protein, immunoglobulins with repeated exchanges; U&E.[3][16]

– If within a study: repeat ageing-biomarker panel at predefined intervals, interpreted cautiously as surrogates.

Timepoints (pragmatic, expert-consensus): pre-each-session labs; short-term review 1–2 weeks post-course; medium-term 3 months; long-term 6–12 months (essential given the signal of possible epigenetic-ageing acceleration with some protocols).[3][4]

Adverse effects (from large disease-indication datasets — generally well tolerated):

– Common/mild (≈4–19% of procedures): paraesthesia/hypocalcaemia, urticaria/pruritus, nausea/vomiting, hypotension/vasovagal reactions, transient electrolyte changes; venipuncture-related events.[14][16][7][8]

– Serious but rare: anaphylactoid reactions (~0.25%), cardiovascular (~0.2%) and respiratory (~0.2%) events; central-line complications (bleeding, pneumo-/haemothorax, thrombosis, infection); hypofibrinogenaemia/bleeding; transfusion-transmitted infection (with plasma products). Procedure-related mortality in pooled data ~0.05%.[15][16]

– Depletion effects with repeated exchange: hypogammaglobulinaemia (infection risk), hypoalbuminaemia, coagulation factor depletion.[3][16]

Actions for abnormalities: treat/prophylax hypocalcaemia with calcium; stop for significant hypotension or allergic reaction and treat; hold/space sessions for falling fibrinogen, IgG or albumin; escalate/refer for any serious cardiovascular, respiratory or access complication.

Interactions: albumin/FFP replacement lowers plasma drug levels (esp. highly protein-bound drugs); coordinate timing of essential medications around sessions. ACE inhibitors + apheresis → atypical reactions. IVIG adds thrombotic, renal and aseptic-meningitis risk.[11]

Special populations: avoid in pregnancy/breastfeeding, significant renal/hepatic impairment, and frailty for longevity intent; use only with specialist input and never outside a research framework.

8. Contraindications and cautions

– Absolute: haemodynamic instability; active major bleeding or severe uncorrected coagulopathy; known anaphylaxis to albumin/plasma/replacement fluid; sepsis/active serious infection.

– Relative / specialist advice needed: significant cardiac or cerebrovascular disease; hypoalbuminaemia/malnutrition; thrombocytopenia; poor vascular access requiring central line in a healthy person; hypogammaglobulinaemia; ACE inhibitor therapy; older frail adults; hepatic impairment.

– Harm likely to outweigh benefit with current evidence: healthy midlife/athletic adults seeking “rejuvenation”; any use of no-replacement plasmapheresis protocols for anti-ageing (possible acceleration of epigenetic ageing).[3][4]

9. Practical management scenarios

Scenario A — Middle-aged adult with multiple cardiometabolic risk factors requesting plasma dilution:

– Recommendation: Avoid / restrict to research only (Strong, against routine use). Plasma dilution does not durably improve cardiometabolic risk; lipid changes are transient.[3]

– Stepwise: (1) Assess and optimise guideline-based risk management (statin/other lipid therapy, BP, glycaemia, lifestyle) — this is where the mortality benefit lies. (2) Shared decision-making: explain no proven longevity benefit, biomarker-only and conflicting evidence, cost and procedural risk. (3) If the patient still wishes to proceed, only within a registered trial/registry with albumin-replacement TPE and full consent. (4) Monitor as above. (5) Stop for any significant adverse event or falling albumin/Ig/fibrinogen.

Scenario B — Older, frail patient with multimorbidity:

– Recommendation: Avoid (Strong). Frailty, cardiovascular disease and central-access needs concentrate the serious-harm risk, with no offsetting evidence of benefit.[15][7]

– Stepwise: comprehensive geriatric assessment; optimise reversible contributors to decline (deprescribing, nutrition, exercise, sensory/cognitive support); do not offer plasma dilution. If cognitive impairment with AD biomarkers, discuss disease-specific trials of TPE rather than longevity use.[5][8]

Scenario C — Patient already under specialist care wanting plasma dilution as an adjunct:

– Recommendation: Consider only in research, with specialist co-management (Conditional).

– Stepwise: (1) Confirm no absolute contraindication and liaise with the treating specialist. (2) Consent covering unproven benefit and drug-clearance interactions (protein-bound drug levels fall with albumin exchange). (3) If proceeding, albumin-replacement TPE within a trial/registry; schedule essential medications around sessions. (4) Monitor labs each session and biomarkers per protocol. (5) Escalate/refer for adverse events; stop if no meaningful benefit or if surrogates worsen.

10. Research gaps and future directions

– Clinical endpoints: no RCT has tested mortality, incident age-related disease, frailty or validated function — the decisive gap. Biomarker changes must not be equated with clinical benefit.[4][12]

– Protocol definition: optimal replacement fluid (albumin vs young plasma vs saline), exchange volume, frequency, course length and whether IVIG adds value beyond its risks are all unresolved.[11][12]

– Reconciling conflicting data: why albumin-replacement TPE appears biomarker-favourable while no-replacement plasmapheresis may accelerate epigenetic ageing needs mechanistic clarification.[3][1][4]

– Patient selection: prospective validation of any baseline predictor (e.g. inflammaging phenotype).[11]

– Long-term safety of repeated exchange in healthy people (immunoglobulin/albumin depletion, cumulative access risk).[3][16]

– Recommendation for practice: until adequately powered RCTs with clinical endpoints report, plasma dilution for longevity should be confined to well-designed clinical trials or prospective registries with standardised biomarkers and independent oversight.[12]

References

1. Old Plasma Dilution Reduces Human Biological Age: A Clinical Study. Kim D, Kiprov DD, Luellen C, et al. GeroScience. 2022;44(6):2701-2720. doi:10.1007/s11357-022-00645-w.
2. Aging and Brain Rejuvenation as Systemic Events. Bouchard J, Villeda SA. Journal of Neurochemistry. 2015;132(1):5-19. doi:10.1111/jnc.12969.
3. Human Clinical Trial of Plasmapheresis Effects on Biomarkers of Aging (Efficacy and Safety Trial). Borsky P, Holmannova D, Parova H, et al. Scientific Reports. 2025;15(1):21059. doi:10.1038/s41598-025-05396-0.
4. Turning Back Time: A Comprehensive List of Interventions That Decrease Next-Generation Epigenetic Aging Clocks in Humans. Johnson AA, Sinclair DA. Frontiers in Genetics. 2026;17:1836446. doi:10.3389/fgene.2026.1836446.
5. Interstitial Fluid Rejuvenation Through Young-Donor Plasma Exchange in Cognitively Impaired Patients: A Pilot Safety and Feasibility Study. Søraas A, Engvig A, Alnæs D, et al. GeroScience. 2026;:10.1007/s11357-026-02435-0. doi:10.1007/s11357-026-02435-0.
6. Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study. Sha SJ, Deutsch GK, Tian L, et al. JAMA Neurology. 2019;76(1):35-40. doi:10.1001/jamaneurol.2018.3288.
7. Therapeutic Plasma Exchange for Myasthenia Gravis, Guillain-Barre Syndrome, and Other Immune-Mediated Neurological Diseases, Over a 40-Year Experience. Fernández-Fournier M, Kerguelen A, Rodríguez de Rivera FJ, et al. Expert Review of Neurotherapeutics. 2022;22(10):897-903. doi:10.1080/14737175.2022.2147827.
8. A Real-World Study on the Safety and Efficacy of Therapeutic Plasma Exchange in Patients With Alzheimer’s Disease. Taragano F, Seinhart D, Epstein P, et al. Journal of Alzheimer’s Disease : JAD. 2025;108(1):129-141. doi:10.1177/13872877251375430.
9. Apheresis for Senescence: Targeting the Senescence-Associated Secretory Phenotype to Delay Aging and Age-Related Diseases. Akgun Y. Ageing Research Reviews. 2025;:102832. doi:10.1016/j.arr.2025.102832.
10. Blood as the Mirror and Modulator of Aging: Mechanistic Insights and Rejuvenation Strategies. Kim E, Kang JS, Yang YR. Experimental & Molecular Medicine. 2026;58(4):1053-1062. doi:10.1038/s12276-026-01688-1.
11. Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange. Fuentealba M, Kiprov D, Schneider K, et al. Aging Cell. 2025;:e70103. doi:10.1111/acel.70103.
12. Plasma-Based Strategies for Systemic Rejuvenation: Critical Perspectives on Clinical Translation. Gulej R, Patai R, Ungvari A, et al. GeroScience. 2026;48(3):4571-4584. doi:10.1007/s11357-026-02136-8.
13. Research Progress on Blood Therapy for Anti-Aging. Liu S, Wang S, Dong Y, Yang S, Yao C. Journal of Advanced Research. 2026;82:981-998. doi:10.1016/j.jare.2025.07.039.
14. Complications of Therapeutic Plasma Exchange: A Retrospective Study of 1201 Procedures in 435 Children. Lu J, Zhang L, Xia C, Tao Y. Medicine. 2019;98(50):e18308. doi:10.1097/MD.0000000000018308.
15. Visual Outcomes of Plasma Exchange for Acute Optic Neuritis: A Report by the American Academy of Ophthalmology. Chen JJ, Oke I, Dinkin MJ, et al. Ophthalmology. 2026;133(5):680-689. doi:10.1016/j.ophtha.2025.12.027.
16. Therapeutic Plasma Exchange: Complications and Management. Mokrzycki MH, Kaplan AA. American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation. 1994;23(6):817-27. doi:10.1016/s0272-6386(12)80135-1.